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Abstract Appican produced by rat C6 glioma cells, the chon-
droitin sulfate (CS) proteoglycan form of the amyloid precursor
protein, contains an E disaccharide, ^GlcUA-GalNAc(4,6-O-di-
sulfate)^, in its CS chain. In this study, the appican CS chain
from rat C6 glioma cells was shown to speci¢cally bind several
growth/di¡erentiation factors including midkine (MK) and plei-
otrophin (PTN). In contrast, the appican CS from SH-SY5Y
neuroblastoma cells contained no E disaccharide and showed no
binding to either MK or PTN. These ¢ndings indicate that the
E motif is essential in the interaction of the appican CS chain
with growth/di¡erentiation factors, and suggest that glial appi-
can may mediate the regulation of neuronal cell adhesion and
migration and/or neurite outgrowth.
1 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder of
the brain, characterized by neuritic plaques and neuro¢bril-
lary tangles. The amyloid L (AL) peptide, found in the brain
amyloid depositions of AD patients, is generated by the pro-
teolytic processing of the amyloid precursor protein (ALPP)
[1]. Speci¢c ALPP mutations are associated with familial AD,
although it is not clear how ALPP mutations precipitate the
AD phenotypes [2]. The ALPP gene consists of 19 exons and
alternative splicing of these exons results in the production of
several ALPP isoforms [3^6]. An ALPP isoform lacking exon
15 is the protein component of appican, the chondroitin sul-
fate (CS) proteoglycan (PG) form of ALPP [7]. Although the
biological functions of ALPP are not well de¢ned, they have
been implicated in cell adhesion and neurite outgrowth pro-
motion [8^10]. Recently we reported that the CS chain of
appican produced by rat C6 glioma cells contains the over-
sulfated E disaccharide motif in signi¢cant proportion (14.3%)
[11], and may thereby be involved in the biological activities
of ALPP.
CS glycosaminoglycans (GAGs) are complex sulfated poly-
saccharides with a backbone structure composed of a repeat-
ing disaccharide building unit of ^4GlcUAL1-3GalNAcL1^.
This simple repeat structure undergoes extensive modi¢cation
by sulfation at the C2 or C3 position of D-glucuronic acid
(GlcUA) residues and/or the C4 or C6 position of N-acetyl-
D-galactosamine (GalNAc) residues during biosynthesis [12].
Diversity in sulfation results in structural variability of CS
chains, which is the basis for their functional diversity. Over-
sulfated CS variants CS-D and CS-E promote neurite out-
growth [13^15], and are characterized by peculiar disulfated
disaccharide motifs including GlcUA(2-O-sulfate)L1-4Gal-
NAc(6-O-sulfate), or GlcUAL1-3GalNAc(4,6-O-disulfate) (E
motif), in CS-D or CS-E, respectively. Recently Deepa et al.
[16] demonstrated that squid cartilage CS-E rich in the E
motif bound speci¢cally and with high a⁄nity to heparin-
binding growth/di¡erentiation factors such as midkine
(MK), pleiotrophin (PTN), heparin-binding epidermal growth
factor-like growth factor (HB-EGF) and several ¢broblast
growth factors (FGFs). Zou et al. [17] showed that versican,
a CS-PG with a high content of the E disaccharide units, is
the MK-binding component in embryonic mouse brains. In
view of these ¢ndings, we compared the CS chains of appicans
produced by rat C6 glioma cells and SH-SY5Y neuroblastoma
cells in terms of their structure and growth factor-binding
capacities to investigate whether appican with the E unit spe-
ci¢cally binds heparin-binding growth/di¡erentiation factors.
2. Materials and methods
2.1. Materials
Appican from rat C6 glioma cells was prepared as described pre-
viously [11]. To improve the isolation of appican, we constructed a
recombinant cDNA which contains codons for six successive histi-
dines inserted after the signal sequence of the L-ALPP isoform (named
after an original ¢nding in leukocytes). This recombinant cDNA was
cloned into the pcDNA3 expression vector. His-tagged L-ALPP was
expressed in stable transfectants of human neuroblastoma SH-SY5Y
cells and rat glioma C6 cells. The His-tagged L-ALPP was processed
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normally and secreted as soluble L-ALPP and appican. The condi-
tioned medium from the transfectant culture was collected and con-
centrated by ultra¢ltration using a disk membrane of 50 000 molecular
weight cut-o¡. The concentrate was loaded on a nickel column and
the column was washed with 20 mM imidazole. The bound His-tagged
protein was eluted with 100 mM imidazole and the eluate was dia-
lyzed and concentrated. Silver staining showed more than 95% purity
of ALPP consisting of both appican and the non-PG form of L-ALPP.
Appican was further separated from L-ALPP using an ion exchange
column. More than 100 Wg of appican was obtained from 2 l of
conditioned medium from SH-SY5Y transfectants cultured with reti-
noic acid.
Chondroitinase ABC (EC 4.2.2.4), Flavobacterium heparinase (EC
4.2.2.7), heparitinase (EC 4.2.2.8), and CS variant preparations (super
special grade) were purchased from Seikagaku (Tokyo, Japan). Hu-
man recombinant MK and basic FGF (bFGF) were from PeproTech
EC (London, UK), and Genzyme-Techne (Minneapolis, MN, USA),
respectively. Human recombinant PTN and HB-EGF were obtained
from RpD Systems (Minneapolis, MN, USA). NaB3H4 (555 GBq/
mmol) was from American Radiolabeled Chemicals (St. Louis, MO,
USA).
2.2. Preparation of 3H-labeled CS-GAGs of appicans from C6 glioma
cells and SH-SY5Y neuroblastoma cells
Puri¢ed appican (40 Wg) from rat C6 glioma cells was treated with
LiOH to liberate O-linked saccharides as described previously [18,19].
The sample was then treated with 100 Wl of 3.3 mM NaB3H4 (555
GBq/mmol)/0.1 M NaOH at room temperature overnight. The appi-
can preparation (30 Wg) puri¢ed from di¡erentiated neuroblastoma
cells was directly treated with 30 Wl of 1.3 mM NaB3H4 (555 GBq/
mmol)/0.15 M NaOH. Non-radiolabeled 1 M NaBH4/0.1 M NaOH
was added to each sample and the mixture was incubated at room
temperature for 2 h to complete the reaction. The reaction was termi-
nated by adding glacial acetic acid to decompose excess NaBH4. Non-
labeled chondroitin (100 Wg) was added as a carrier to the mixture,
and the 3H-labeled materials were puri¢ed by gel ¢ltration [20]. One
half of the 3H-labeled polysaccharides puri¢ed by Superdex 200 chro-
matography (1.2U105 or 7.4U104 dpm derived from C6 glioma or
SH-SY5Y neuroblastoma appican, respectively) was exhaustively di-
gested with a mixture of heparinase and heparitinase [20] to remove
heparan sulfate (HS) oligosaccharides. An aliquot of each sample
(4000 dpm) was digested with chondroitinase ABC [20]. The digests
were analyzed by gel ¢ltration chromatography on a column of Super-
dex 200 using 0.25 M NH4HCO3/7% 1-propanol as the eluent at a
£ow rate of 0.4 ml/min.
2.3. Disaccharide composition analysis of CS chains of SH-SY5Y
neuroblastoma appican
The CS disaccharide composition of SH-SY5Y neuroblastoma ap-
pican was determined by enzymatic digestion with chondroitinase
ABC as reported [21].
2.4. Filter binding assay
Various amounts (0.15^0.5 Wg) of growth/di¡erentiation factors
were incubated with [3H]CS from appican (4000 dpm) in a total vol-
ume of 50 Wl of 50 mM Tris^HCl (pH 7.3) containing 130 mM NaCl
and 0.5 mg/ml bovine serum albumin (BSA) at room temperature for
3 h. Proteins with any associated [3H]CS were collected on nitrocellu-
lose ¢lters [22], which were monitored by liquid scintillation counting.
2.5. Biotinylation of appican for immobilization
Rat C6 glioma appican was labeled with biotin by reaction of its
free amino groups of the core protein. Twenty Wg of appican was
dissolved in 12 Wl of phosphate-bu¡ered saline (PBS) containing 20
Wg of EZ-Link1Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL, USA)
and incubated at room temperature for 30 min. The biotinylated
appican was puri¢ed using Centricon 30 (Millipore).
2.6. Biosensor analysis of the binding of neuroregulatory factors to
appican
Biosensor analysis was performed using an IAsys instrument (Lab-
systems, Cambridge, UK). Biotinylated appican was immobilized on
the sensor chip surface using an IAsys biotin cuvette. The biotin sur-
face of the cuvette was washed with PBS/Tween-20, and streptavidin
was added at a concentration of 100 Wg/ml. After streptavidin was
captured on the surface, BSA was added for blocking. Biotinylated
appican (4 Wg as appican) was then added to the streptavidin-captured
surface. The appican-immobilized cuvette was used in subsequent ex-
periments to examine interactions of appican with PTN and MK.
Growth factors were added at the indicated concentrations using
PBS/Tween-20, and the association was monitored. In the dissociation
phase, proteins were released with PBS/Tween-20, and the dissociation
of the binding was monitored. The appican surface was regenerated
by the addition of 1 M NaCl. In competition experiments, various CS
variants were preincubated with proteins in PBS/Tween-20 at room
temperature for 5 min, and then the mixture was added to the cuvette.
3. Results
The biological functions of the CS chain attached to ALPP
are mostly unknown. The CS chain of ALPP produced by rat
C6 glioma cells contains the oversulfated E disaccharide unit,
GlcUAL1-4GalNAc(4,6-O-disulfate), in signi¢cant proportion
(14%) [11]. Squid cartilage CS, which contains the E unit in
high proportion (62%), has neurite outgrowth-promoting ac-
tivity [13,15] and interacts with various heparin-binding
growth factors including neuroregulatory factors such as
MK and PTN [16,23]. Hence, the neuroregulatory factors’
binding ability of the CS chain of appican produced by rat
C6 glioma cells was evaluated to better understand the func-
tions of appican in the brain.
3.1. Preparation of a 3H-labeled CS-GAG fraction from rat C6
glioma appican
A 3H-labeled CS-GAG fraction of appican from rat C6
glioma cells was prepared as follows. Puri¢ed appican was
subjected to alkaline NaB3H4 reduction to liberate O-glycans
from the core protein and to radiolabel the reducing ends of
the liberated saccharides. A CS-containing fraction, recovered
by gel ¢ltration on a Superdex 200 column (Fig. 1A), was
digested with a mixture of heparinase and heparitinase, and
the digest was subjected to gel ¢ltration chromatography to
remove the degradation products (Fig. 1B). Approximately
18% of the radiolabeled materials were susceptible to HS
lyases, suggesting that this preparation contained HS-GAG
chains. It remains unclear whether these HS chains were at-
tached to the appican core protein or derived from co-puri¢ed
HS-PGs. More than 90% of the radiolabeled materials in the
HS lyase-resistant peak was digested by chondroitinase ABC
as shown by gel ¢ltration chromatography (Fig. 1C), indicat-
ing that the [3H]CS fraction was at least 90% pure.
3.2. Demonstration of a direct interaction of the appican CS
puri¢ed from C6 glioma cells with heparin-binding growth
factors
Puri¢ed [3H]CS chain fractions were subjected to the nitro-
cellulose ¢lter binding assay to examine whether appican CS
can interact with several heparin-binding growth factors, MK,
PTN, HB-EGF, and bFGF, all of which are expressed in
mammalian brains and interact speci¢cally with squid carti-
lage CS-E [16], despite the fact that they belong to three
di¡erent gene families. All the heparin-binding growth factors
tested bound to the [3H]CS preparation from appican in a
concentration-dependent manner (Fig. 2), although saturation
of the binding could not be tested due to the limited avail-
ability of the commercial growth factors of high costs. The
binding of these growth factors to [3H]CS was abolished by
chondroitinase ABC digestion (data not shown), con¢rming
that these interactions are dependent on the CS chain.
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We also examined the interactions of the growth factors
with the appican CS-PG puri¢ed from C6 glioma cells using
an IAsys resonant mirror optical biosensor. In this binding
assay, appican was biotinylated and immobilized on the sen-
sor chip surface coated with streptavidin. MK or PTN was
added at a concentration of 1 Wg/ml to the immobilized appi-
can, and the time-dependent response (in arc seconds) was
recorded. The sensorgrams in an association phase are shown
in Fig. 3A,B. Response of 30 and 40 arc seconds were ob-
served for MK and PTN, respectively, demonstrating that
both neuroregulatory factors bound to the immobilized appi-
can.
To investigate the speci¢city of the MK and PTN binding
to appican CS-PG, inhibition studies were performed using
various kinds of CS variants. When each CS variant was
added to the appican surface, no interaction was detected
between the appican surface and the CS variant (data not
shown). The ¢ndings from the inhibition studies are illustrated
in Fig. 3C,D. Only the CS-E preparation strongly prevented
the binding of both MK and PTN to appican (Fig. 3). Other
CS variants exhibited no signi¢cant inhibition at 0.5 Wg/ml.
CS-B showed weak inhibition of the MK binding (44% inhi-
bition) when used at high concentration (1.5 Wg/ml) (Fig. 3D).
The results suggest that the E disaccharide motif of the CS
chain is essential for the binding of MK and PTN to appican
CS-PG.
3.3. Comparison of the disaccharide composition of the CS
chain of appican from C6 glioma cells and neuroblastoma
cells
Appican is expressed almost exclusively by glial cells in vivo
[24,25], and promotes neuronal cell adhesion and neurite out-
growth [26,27]. To investigate whether the E disaccharide mo-
Fig. 1. Preparation of [3H]CS chains from C6 glioma appican. The
rat C6 glioma appican preparation was treated with alkaline
NaB3H4 and the 3H-labeled CS chains were recovered by gel ¢ltra-
tion chromatography as described in Section 2. A: An aliquot (7500
dpm) of the puri¢ed fraction was analyzed by gel ¢ltration. B: An-
other aliquot (1.2U105 dpm) was digested with a mixture of hepa-
rinase and heparitinase. Approximately one twentieth of each frac-
tion was used for monitoring by liquid scintillation counting. The
£ow-through fractions, which were resistant to HS lyases and are
indicated by the bar (9.8U104 dpm), were pooled as [3H]CS chains
from appican. C: An aliquot (5000 dpm) of the [3H]CS fraction ob-
tained in B was digested with chondroitinase ABC. At least 90% of
the preparation was susceptible to the enzyme.
Fig. 2. Demonstration of direct binding of the [3H]CS chains from
C6 glioma appican to various heparin-binding growth factors using
¢lter binding assays. The [3H]CS chains from C6 glioma appican
(4000 dpm corresponding to 0.82 Wg of appican CS-PG) (solid lines)
were incubated individually with various amounts of heparin-bind-
ing growth factors, MK (open circles), PTN (open squares), HB-
EGF (closed circles), or bFGF (closed squares). The [3H]CS chains
from SH-SY5Y neuroblastoma appican (4000 dpm corresponding to
0.81 Wg of appican CS-PG) (broken lines) were also incubated with
0.3 Wg of MK (open triangles) or PTN (closed triangles). The bind-
ing to growth factors was quanti¢ed by ¢lter binding assays as de-
scribed in Section 2. Values are expressed as percentages of the ra-
dioactivity added to the samples incubated.
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tif is speci¢c to the appican CS expressed in glioma cells, the
disaccharide composition of the CS chain of appican pro-
duced by C6 glioma cells and neuroblastoma cells was com-
pared. The disaccharide composition of the former was pre-
viously analyzed [11] and that of neuroblastoma appican CS
was carried out in this study by digestion with chondroitinase
ABC, followed by derivatization with a £uorophore 2-amino-
benzamide and anion exchange high performance liquid chro-
matography (HPLC) (Table 1). The predominant component
was vHexUAK1-3GalNAc(4-O-sulfate) accounting for 77.5%
of the total CS. However, in strong contrast to the C6 glioma
appican CS, the disaccharide E motif was not detected in the
SH-SY5Y neuroblastoma appican CS chain, suggesting that
the E disaccharide motif is characteristic for the CS from the
C6 glioma cell-derived appican but not for the CS from the
SH-SY5Y neuroblastoma cell-derived appican.
To evaluate the importance of the E disaccharide motif for
the neuroregulatory factor binding, the CS chain preparation
of appican expressed in SH-SY5Y neuroblastoma cells was
subjected to the ¢lter binding assay. Neither PTN nor MK
exhibited appreciable binding to [3H]CS from SH-SY5Y neu-
roblastoma appican (Fig. 2). These results altogether indicate
that the E disaccharide motif in the appican CS chain is es-
sential in the interaction with MK and PTN.
Fig. 3. Speci¢city analysis of the binding of PTN and MK to the CS-PG appican-immobilized surface in the biosensor IAsys. A,B: Binding of
recombinant PTN (1 Wg/ml) (A) and MK (1 Wg/ml) (B) to the immobilized CS-PG appican puri¢ed from C6 glioma was analyzed by IAsys in
the presence or absence of various CS variants (0.5 Wg/ml), and the overlay sensorgrams are shown. At the position indicated by the open ar-
row in each panel, the recombinant growth factor was added to the cuvette. C,D: Inhibition of the binding of PTN (C) or MK (D) to the ap-
pican-coated surface by various CS variants was analyzed. Recombinant growth factors were preincubated with 0.5 Wg/ml (shaded columns) or
1.5 Wg/ml (open columns) of various CS variants, and each mixture was then added to the appican-immobilized cuvette. The binding of the
growth factors to the sensor surface was quanti¢ed based on the response (arc seconds). Values are the averagesR range from two separate ex-
periments and are expressed as percentages of the response without inhibitors.
Table 1
Disaccharide composition of appican CS from C6 glioma and SH-SY5Y neuroblastoma cells
2-Aminobenzamide-labeled disaccharides Proportion (%)
Gliomaa Neuroblastoma
vHexUAK1-3GalNAc 1.2 NDb
vHexUAK1-3GalNAc(4-O-sulfate) 81.2 77.5
vHexUAK1-3GalNAc(6-O-sulfate) 3.3 22.5
vHexUA(2-O-sulfate)K1-3GalNAc(6-O-sulfate) ND ND
vHexUAK1-3GalNAc(4,6-O-disulfate) 14.3 ND
vHexUA(2-O-sulfate)K1-3GalNAc(4,6-O-disulfate) ND ND
The puri¢ed appican from SH-SY5Y neuroblastoma cells was digested with chondroitinase ABC. The digest was derivatized with 2-aminoben-
zamide [21], and the 2-aminobenzamide-derivatized oligosaccharides were analyzed by HPLC as described in Section 2.
aThe CS disaccharide composition of C6 glioma appican was taken from the data in [11].
bND, not detected.
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4. Discussion
A number of growth/di¡erentiation factors have been
postulated to be involved in brain development [28]. In this
study, we show that the CS chain of appican, the CS-PG form
of ALPP produced by C6 glioma cells, interacts with various
heparin-binding growth factors, including MK, PTN, bFGF,
and HB-EGF. These data show that CS-GAG chains from
central nervous system-derived cells are able to bind growth
factors. Recently Zou et al. [17] isolated CS/DS-GAG chains
with MK-binding capacity from day 13 embryonic mouse
brain using a MK a⁄nity column and found a progressive
increase in the E disaccharide unit in the higher a⁄nity frac-
tions, which is consistent with the present ¢ndings. Maeda et
al. [29] showed that PTN binds to the transmembrane signal-
transducing receptor-type protein tyrosine phosphatase 6B4-
PG/RPTPj, a major CS-PG in the brain, and that the CS side
chains along with the core protein constitute the binding site.
MK and PTN have neuroregulatory activities including stim-
ulation of neuronal cell adhesion [23] and promotion of neu-
rite outgrowth [30]. HB-EGF is found in cerebral neurons and
its expression is increased after hypoxic or ischemic injury
[31]. bFGF is an important growth factor that in£uences
cell morphology, migration [32] and neural di¡erentiation
[33]. We recently reported that CS-E derived from squid car-
tilage speci¢cally interacts with multiple heparin-binding
growth factors including those used in this study [16], suggest-
ing that these proteins interact not only with HS-PG but also
with CS-PG on the cell surface. In fact, PTN binds to the cell
surface receptor 6B4-PG/RPTPj through the receptor’s CS
chains, and the binding is inhibited by CS-B, CS-C, CS-D
and CS-E [29].
In contrast to the CS chain of the C6 glioma appican, the
CS chain from SH-SY5Y neuroblastoma appican, which lacks
the E motif, failed to bind these factors, suggesting that the E
motif is necessary for the interaction between appican and the
growth factors. It will be interesting to further investigate
whether the structural and functional di¡erences in the CS
chains of appicans from these two di¡erent sources represent
glioma cell-speci¢c or cell type-dependent characteristics using
multiple glioma and neuroblastoma cell lines.
Based on the data of molecular size and disaccharide com-
position of the C6 glioma appican CS [11], the number of E
units in a single appican CS chain is calculated to be 7^14.
These E units could be arranged in clusters forming consec-
utive sequences such as E-E or E-E-E similar to those re-
ported by Kawashima et al. [34] for the squid cartilage CS-
E-derived tetrasaccharide sequence, which interacts directly
with L- and P-selectin as well as chemokines. Alternatively,
characteristic sequences including scattered E units may serve
as functional domain structures recognized by protein ligands.
Salinero et al. [27] puri¢ed appican PGs from human con-
trol and AD brains and veri¢ed their stimulatory e¡ects on
the neurite extension of hippocampal neurons. Since the
ALPP core protein is much less potent in promoting neurite
outgrowth than appican [27], the CS chain of appican is as-
sumed to be mainly responsible for the activity. Compared
with appican from control brains, appican from AD brains
has higher neurite outgrowth activity [27], indicating that ¢ne
sulfation structures of the appican CS chain may di¡er be-
tween control and AD brains. A proportion of the E disac-
charide motif would in£uence the biological activity of appi-
can in pathological situations. An augmentation of appican in
the AD brain [27] may represent a positive response aiming at
recovering or protecting damaged brains.
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